Xequel Bio

Xequel Bio

Biotechnology, 777 Taylor St., Fort Worth, Texas, 76102, United States, 11-50 Employees

firststringresearch.com

  • twitter
  • LinkedIn

phone no Phone Number: 84********

Who is XEQUEL BIO

Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will e...

Read More

map
  • 777 Taylor St., Fort Worth, Texas, 76102, United States Headquarters: 777 Taylor St., Fort Worth, Texas, 76102, United States
  • 2005 Date Founded: 2005
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from XEQUEL BIO

Xequel Bio Org Chart and Mapping

Employees

Irina Adamova

Executive Assistant/Office Manager

Kayla Wilson

Associate Director, Strategic Initiatives

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Xequel Bio

Answer: Xequel Bio's headquarters are located at 777 Taylor St., Fort Worth, Texas, 76102, United States

Answer: Xequel Bio's phone number is 84********

Answer: Xequel Bio's official website is https://firststringresearch.com

Answer: Xequel Bio's revenue is $1 Million to $5 Million

Answer: Xequel Bio's SIC: 2834

Answer: Xequel Bio's NAICS: 325412

Answer: Xequel Bio has 11-50 employees

Answer: Xequel Bio is in Biotechnology

Answer: Xequel Bio contact info: Phone number: 84******** Website: https://firststringresearch.com

Answer: Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the bodys response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. The Companys lead clinical programs include Granexin gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access